Search Results - "CHAMBOST, H"

Assessing risk factors: prevention of inhibitors in haemophilia by CHAMBOST, H.

“…The formation of antibodies against factor VIII or factor IX that inhibit replacement therapy is currently the most serious treatment‐related complication…”
Get full text

Platelet transfusion and immunization anti-Rh1: implication for immunoprophylaxis by Chambost, H

“…Rhesus (Rh) antigens are not expressed on platelets but residual red cells carry the risk of anti-D iso-immunization in transfusion recipients of platelet…”
Get more information

Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study by Bernard, F, Auquier, P, Herrmann, I, Contet, A, Poiree, M, Demeocq, F, Plantaz, D, Galambrun, C, Barlogis, V, Berbis, J, Garnier, F, Sirvent, N, Kanold, J, Chastagner, P, Chambost, H, Michel, G

“…The purpose of this multicenter study was to compare the long-term impact of a preparative regimen with either BUBU or TBI on health status and quality of life…”
Get full text

Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds by Andersson, Nadine G, Chalmers, Elizabeth A, Kenet, Gili, Ljung, Rolf, Mäkipernaa, Anne, Chambost, Hervé

“…The optimal mode of delivery for a pregnant hemophilia carrier is still a matter of debate. The aim of the study was to determine the incidence of intracranial…”
Get full text

Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry by Chambost, H., Santagostino, E., Laffan, M., Kavakli, K.

“…Summary The ONE Registry (OR) was an international prospective observational study of on‐demand recombinant factor VIIa (rFVIIa) treatment for mild to moderate…”
Get full text

Prophylaxis in patients with haemophilia: introduction by CHAMBOST, H.

Get full text

Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation by Farnault, L, Gertner-Dardenne, J, Gondois-Rey, F, Michel, G, Chambost, H, Hirsch, I, Olive, D

Get full text

Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations by HERMANS, C., ALTISENT, C., BATOROVA, A., CHAMBOST, H., DE MOERLOOSE, P., KARAFOULIDOU, A., KLAMROTH, R., RICHARDS, M., WHITE, B., DOLAN, G.

“…Although most surgical and invasive procedures can be performed safely in patients with haemophilia, the optimal level and duration of replacement therapy…”
Get full text

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study by Liesner, R. J., Abashidze, M., Aleinikova, O., Altisent, C., Belletrutti, M. J., Borel‐Derlon, A., Carcao, M., Chambost, H., Chan, A. K. C., Dubey, L., Ducore, J., Fouzia, N. A., Gattens, M., Gruel, Y., Guillet, B., Kavardakova, N., El Khorassani, M., Klukowska, A., Lambert, T., Lohade, S., Sigaud, M., Turea, V., Wu, J. K. M., Vdovin, V., Pavlova, A., Jansen, M., Belyanskaya, L., Walter, O., Knaub, S., Neufeld, E. J.

“…Introduction Nuwiq® (Human‐cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein…”
Get full text

α1‐antitrypsin Pittsburgh and plasmin‐mediated proteolysis by Henneuse, A., Suchon, P., Chambost, H., Morange, P. E., Frere, C., Alessi, M. C.

“…Essentials Patients with α‐1‐antitrypsin (α1‐AT) Pittsburgh exhibit a mild bleeding tendency. A new case of α1‐AT Pittsburgh with suspected high…”
Get full text

FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders by Doncarli, Alexandra, Demiguel, Virginie, Canu, Irina Guseva, Goulet, Véronique, Bayart, Sophie, Calvez, Thierry, Castet, Sabine, Dalibard, Vincent, Demay, Yohan, Frotscher, Birgit, Goudemand, Jenny, Lambert, Thierry, Milien, Vanessa, Oudot, Caroline, Sannié, Thomas, Chambost, Hervé

“…FranceCoag is an ongoing open prospective multicentre cohort project aimed at improving epidemiological knowledge about inherited bleeding disorders in France…”
Get full text

Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling by Jourdy, Y., Chatron, N., Fretigny, M., Carage, M. L., Chambost, H., Claeyssens‐Donadel, S., Roussel‐Robert, V., Negrier, C., Sanlaville, D., Vinciguerra, C.

“…Background Genomic inversions are usually balanced, but unusual patterns have been described in haemophilia A (HA) patients for intron 22 (Inv22) and intron 1…”
Get full text

Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study by Sirvent, A, Auquier, P, Oudin, C, Bertrand, Y, Bohrer, S, Chastagner, P, Poirée, M, Kanold, J, Thouvenin, S, Perel, Y, Plantaz, D, Tabone, M-D, Yakouben, K, Gandemer, V, Lutz, P, Sirvent, N, Vercasson, C, Berbis, J, Chambost, H, Leverger, G, Baruchel, A, Michel, G

“…Data on post-transplant iron overload (IO) are scarce in pediatrics. We conducted a prospective multicenter cohort study (Leucémie de l’Enfant et de…”
Get full text

Transfusion plaquettaire et iso-immunisation anti-Rh1 : intérêt de la séroprévention by Chambost, H.

“…En l’absence d’expression des antigènes Rhésus par les plaquettes, les globules rouges résiduels exposent les receveurs de transfusions de concentrés…”
Get full text

Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study by Kavakli, K., Demartis, F., Karimi, M., Eshghi, P., Neme, D., Chambost, H., Sommer, L., Zak, M., Benson, G.

“…Introduction A room temperature stable formulation of recombinant activated factor VII (NovoSeven®), allowing convenient storage and therefore improved…”
Get full text

Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation by Farnault, L, Gertner-Dardenne, J, Gondois-Rey, F, Michel, G, Chambost, H, Hirsch, I, Olive, D

Get full text

Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies by CARCAO, M., CHAMBOST, H., LJUNG, R.

“…Data from prospective studies clearly demonstrate the efficacy of prophylactic treatment of haemophilia in reducing joint‐ or life‐threatening bleeding and the…”
Get full text

Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation by MICHEL, G, BORDIGONI, P, AUQUIER, P, SIMEONI, M.-C, CURTILLET, C, HOXHA, S, ROBITAIL, S, THURET, I, PALL-KONDOLFF, S, CHAMBOST, H, ORBICINI, D

“…We compared late side effects and quality of life (QoL) in 430 survivors of childhood acute leukaemia based on whether they had undergone haematopoietic cell…”
Get full text

Cancer detection and management in patients with haemophilia: a retrospective European multicentre study by Biron-Andreani, C., de Moerloose, P., D'oiron, R., Chambost, H., Schved, J.-F., Hermans, C.

“…Summary Lymphomas or hepatocarcinomas related to blood‐borne transmitted diseases are well‐known malignancies in persons with haemophilia (PWH). However,…”
Get full text

Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors by Lebreton, A, Lapalud, P, Chambost, H, Biron-Andréani, C, Morange, P-E, Combescure, C, Marquès-Verdier, A, Berger, C, Schved, J-F, Granier, C, Lavigne-Lissalde, G

“…Antibodies (inhibitors and non-neutralising antibodies [NNA]) directed against factor VIII (FVIII) remain the main iatrogenic complication in haemophilia A…”
Get more information